Novartis Takes $665m Bid for Selexys

Sep 21, 2012, 08:00 AM by Michael Croft

Tulsa World | In addition to $23 million of Series A financing, Selexys Pharmaceuticals Corp. of Oklahoma City has struck an agreement with Novartis that could lead to the company's acquisition for up to $665 million for its sickle cell treatment.

September 21, 2012 | In addition to $23 million of Series A financing, Selexys Pharmaceuticals Corp. of Oklahoma City has struck an agreement with Novartis that could lead to the company's acquisition for up to $665 million. Novartis has been granted an exclusive option to acquire Selexys and its lead asset, the anti-P-selectin antibody SelG1, following the successful completion of a Phase 2 clinical study in patients with sickle cell disease. Tulsa World